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P U B L I S H E D B Y E L S E V I E R I N C .LettersUrinary Hyaluronic Acid
as an Early Predictor of
Acute Kidney Injury After
Cardiac SurgeryCardiac surgery–associated acute kidney injury (CSA-
AKI) is a frequent, complex clinical problem in
patients undergoing cardiac surgery with cardiopul-
monary bypass (CPB). CSA-AKI is an important pre-
dictor of morbidity and mortality after cardiac
surgery (1).
Changes in serum creatinine level and/or urine
output, as proposed in the current consensus criteria
(2), do not allow for the diagnosis of CSA-AKI until 24
to 48 h after surgery (3). Although treatment options
for AKI are still limited, prevention of further damage
as early as possible and timely prognostication are
crucial to improve outcomes.
Newer biomarkers exist (e.g., urinary interleukin-
18, urinary NGAL, or urinary KIM-1), but the perfor-
mance of these markers to predict CSA-AKI is not
optimal. Hyaluronic acid (HA) is a crucial, structural
component of the extracellular matrix in many or-
gans, including the kidneys. A broad spectrum of HA-
mediated cell and organ function make HA a highly
interesting target with respect to AKI (4). Here, we
tested whether urinary HA (uHA) concentration can
predict CSA-AKI earlier than currently used clinical
parameters. We studied patients at high risk for CSA-
AKI, as identiﬁed by a Cleveland Clinic Score $6; this
score is composed of 13 pre-operative risk factors,
including patient characteristics, comorbidities, and
type of surgery (5). Our primary endpoint was the
development of CSA-AKI, as deﬁned by the KDIGO
criteria (2).
Fifty patients with a Cleveland Clinic Score $6
were included in our study, and 26 (52%) of these
patients developed AKI. Patients who did not develop
CSA-AKI did not have a signiﬁcant increase in uHA
concentration post-operatively (all p > 0.05). In
contrast, patients who developed CSA-AKI had a
strong, signiﬁcant increase in uHA concentration as
early as 4 h after surgery and lasting until 24 h after
surgery (compared with pre-CPB, all p # 0.05)(Fig. 1A). These results remained unchanged when the
uHA concentration was normalized for urinary
creatinine concentration; only the time proﬁle of the
point estimates for the uHA shifted slightly (Fig. 1B).
Renal HA expression is increased in some chronic
disease states, such as diabetes and nephrolithiasis,
which in turn have the potential to lead to chronic
renal insufﬁciency (4). Moreover, both diabetes and
pre-operative renal insufﬁciency increase the risk of
CSA-AKI (5). In our study population, baseline uHA
concentrations were not elevated in patients with
diabetes or pre-operative renal insufﬁciency, sug-
gesting that uHA concentration can serve as a marker
of AKI. The cause of elevated uHA concentrations
during AKI remains unknown at this time.
To examine whether uHA can predict CSA-AKI, we
calculated receiver-operating characteristics and
their respective area under the curve (AUC). For
uHA, the AUC was 0.89 (95% conﬁdence interval
[CI]: 0.79 to 0.99), 0.94 (95% CI: 0.87 to 1.00), and
0.89 (95% CI: 0.77 to 0.99) at 4 h, 12 h, and 24 h after
CPB, respectively (Fig. 1C). The AUC for uHA was
signiﬁcantly greater than that for the 2 existing bio-
markers, suggesting better diagnostic performance of
uHA. Patients with a uHA concentration >400 ng/ml
at 12 h after surgery had a 6.8-fold higher risk of
CSA-AKI than those with a uHA concentration
<400 ng/ml.
When added to a 7-parameter clinical model, uHA
signiﬁcantly improved risk prediction for our primary
endpoint (Fig. 1E). uHA remained strongly associated
with AKI in this model.
To our knowledge, this is the ﬁrst study describing
uHA as an early predictive biomarker of CSA-AKI. We
showed that uHA concentrations increase as early as
4 h after CPB in those who later develop CSA-AKI,
whereas uHA concentrations remain unchanged in
patients who do not develop AKI. An AUC >0.9 sug-
gests better performance than other new biomarkers.
In addition, uHA showed excellent performance
despite heterogeneous comorbidities in our patient
population, which is a strength of our study. Pre-
existing renal insufﬁciency did not affect baseline
uHA concentrations.
Our study has several limitations that do not allow
us to generalize the ﬁndings. Most importantly, we
studied only a small number of patients at high risk
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FIGURE 1 Analysis of uHA Concentrations and ROC Curves at 4 h, 12 h, and 24 h
(A) Mean uHA concentrations at various time points before and after cardiopulmonary
bypass (CPB). (B) uHA concentrations corrected for urine creatinine excretion. Error bars
are SE. *p # 0.05 between groups (AKI, non-AKI) at the respective time point without
adjustment for multiple comparisons. (C) ROC curves for HA at 4 h, 12 h, and 24 h. (D) The
AUC for HA and existing biomarkers of AKI. The AUC for uHA is signiﬁcantly greater than
that for the existing biomarkers (HA compared with Cystatin C: p ¼ 0.0128; HA compared
with KIM-1: p ¼ 0.0001). #p < 0.05 versus other biomarkers. (E) Cox proportional hazards
models for HA and clinical covariates. AKI ¼ acute kidney injury; AUC ¼ area under the
curve; CI ¼ conﬁdence interval; HA ¼ hyaluronic acid; ROC ¼ receiver-operating charac-
teristic; uHA ¼ urinary hyaluronic acid.
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738for CSA-AKI at one institution. Our results require
validation in larger multicenter studies.
In summary, our preliminary study indicates that
uHA has the potential to become a highly useful
biomarker for early prediction of CSA-AKI.*Alexander Zarbock, MD
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Lewis Index Be More
Speciﬁc, Without
Marked Reduction of
Sensitivity, in ECG
Diagnosis of RVH?Whitman et al. (1) should be congratulated for their
important contribution on the electrocardiogram
(ECG) diagnosis of right ventricular hypertrophy
(RVH). The authors’ database comprised 3,719
patients with normal left ventricular morphology
and function who had an ECG and a cardiac magnetic
resonance imaging–based assessment for RVH and
were free of clinical cardiac disease, although some
patients had hypertension, diabetes, or hypercho-
lesterolemia. The authors implemented 22 ECG
diagnostic criteria (Table 1 in their paper) and found
that “a total of 6% had RVH, which was generally
mild,” and that the “ECG criteria were speciﬁc
(many >95%) but had low sensitivity.The positive
predictive values were not sufﬁciently high as to be
